Vergara, Maxcryl Klenmae M.

HRN: 21-91-25  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/19/2022
CO-AMOXICLAV 625MG (TAB)
10/19/2022
10/26/2022
ORAL
625mg/tab
BID
S/P 2° RMLE With Episiotomy & Episiorrhaphy
Waiting Final Action 
10/20/2022
CEFTRIAXONE 1G (VIAL)
10/20/2022
10/27/2022
IV
2gm
OD
UTI, Leukocytosis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: